Find an expert

I am a Research Fellow and Leader in Pain Relief Innovation at AIBN, UQ. My research interests sit at the interface of drug delivery and the pain field. My overarching research goal is to improve the quality of day to day life of patients suffering from chronic pain, by applying nanotechnology to the development of novel highly effective pain-killer products for improving chronic pain management. I am looking for highly motivated postgraduate students.

I also enjoy volunteering within the academic community, most notably as Head of the SBMS ECR Committee and Treasurer for The Queensland Chinese Association of Scientists and Engineers (QCASE). I am currently serving as guest editor of Pain Research and Management.and JoVE Methods Collection.

Research Interests

My research is focusing on nano-based drug formulation and development to improve chronic pain management. I have a broad and unique background in both pharmacology and drug delivery systems, with specific expertise in the development of novel drug products and testing their analgesic efficacy and safety including pharmacokinetic and pharmacodynamic studies. To date, I have established five different techniques to produce painkiller–loaded nanoparticles and nanofibers aimed at improving pain relief for patients where currently available pain-killers either lack efficacy or produce dose-limiting side-effects. For example, there is a small and very potent peptide that has been on the market as a chemical for over 10 years but which cannot be used as a therapeutic due to its short half-life and poor oral bioavailability. In the form of my nanoparticles, that peptide has the potential to become an oral treatment for improving pain management in patients whose pain is currently poorly alleviated by clinically used pain-killers. I have significant expertise in the use of rodent pain models to assess novel analgesics, and I have received excellent training in conducting research in accordance with the stringent requirements of the Quality Management System (quality accreditations (GLP and ISO17025) from NATA). Together, my knowledge, skills and experience will facilitate the efficient translation of my research from the bench to the clinic.

The current focus of the lab is on the development of drug-products to solve one of the largest unmet medical needs in the pain field through use of sustainable materials. 1) We are developing multifunctional sutures including biodegradable pain relief sutures. 2) We are developing my innovative novel nanoparticles, which deliver innate-immune targeting peptides for the treatment of cancer and cancer-related pain. We are establishing a platform for the development of safe, effective delivery for other small molecule peptide drugs in general to pave their way to clinical trials. 3) Our research also investigates the role of C5a and C3a, estrogen, etc. in the pathogenesis of chronic pain including neuropathic pain, cancer-related pain, low back pain and OA pain.

We work in collaboration with other leading Australian and international researchers to stay at the forefront of the drug delivery systems field and the pain field. We also provide preclinical evaluation of novel compounds and formulations.

MBChB FRCA FANZCA FFICM PhD

Queensland Brain Institute

Dr Massimo A. Hilliard received his PhD in Biological Chemistry and Molecular Biology in 2001 from the University of Naples, Italy. His experimental work, performed at the Institute of Genetics and Biophysics of the CNR (Italian National Council of Research), was aimed at understanding the neuronal and genetic basis of aversive taste behavior (bitter taste) in C. elegans.

During his first postdoc at the University of California, San Diego, using the Ca2+ indicator Cameleon he published the first direct visualisation of chemosensory activity in C. elegans neurons. In his second postdoctoral work at the University of California, San Francisco and at The Rockefeller University, he switched from neuronal function to neuronal development, focusing in particular on how neurons establish and orient their polarity with respect to extracellular cues.

From September 2007, he is at the Queensland Brain Institute where he established an independent laboratory.

Paul W. Hodges DSc MedDr PhD BPhty(Hons) FAA FACP APAM(Hon) is an National Health and Medical Research Council (NHMRC) Leadership Fellow (Level 3), Professor and Director of the Centre for Innovation in Pain and Health Research (CIPHeR) at The University of Queensland (UQ). He is lead chief investigator on an NHMRC Synergy Grant that includes colleagues from the Universities of Queensland, Adelaide and South Australia, and the South Australian Health and Medical Research Institute. Paul is a Fellow of the Australian Academy of Science, which is a Fellowship of the nation’s most distinguished scientists, elected by their peers for outstanding research that has pushed back the frontiers of knowledge. He is also a Fellow of the Australian College of Physiotherapists, the Australian Academy of Health and Medical Science, and was made an Honoured member of the Australian Physiotherapy Association, their highest honour.

Paul is a recognised world leader in movement control, pain and rehabilitation. His unique comprehensive research approach from molecular biology to brain physiology and human function has led to discoveries that have transformed understanding of why people move differently in pain. His innovative research has also led to discoveries of changes in neuromuscular function across a diverse range of conditions from incontinence to breathing disorders. These observations have been translated into effective treatments that have been tested and implemented internationally.

Paul has received numerous national and international research awards that span basic and clinical science. These include the premier international award for spine research (ISSLS Prize) on five occasions; three times in Basic Science (2006, 2011, 2019) and twice in Clinical Science (2018, 2021). International awards in basic science include the SusanneKlein-Vogelbach Award (2010) and the Delsys Prize for Innovation in Electromyography (2009). National medical research awards include the NHMRC Achievement Award (2011). He has also received national community-based leadership awards including the Young Australian of the Year Award in Science and Technology (1997), Future Summit Australian Leadership Award (2010), and Emerging Leader Award (Next 100 Awards, 2009).

Paul is the Chair of the Terminology Task Force for the International Association for the Study of Pain, Chair of the Consensus for Experimental Design in Electromypgraphy for the International Society for Electrophysiology and Kinesiology and has been the Chair/Co-Chair for several major international conferences. He has led major international consortia to bring together leaders from multiple disciplines to understand pain.

Dr. Aleksandr Kakinen is an NHMRC Emerging Leadership Fellow at the Australian Institute for Bioengineering and Nanotechnology (AIBN), University of Queensland. He completed his PhD in 2014 at Tallinn University of Technology, Estonia, and held a postdoctoral fellowship at Monash Institute of Pharmaceutical Sciences from 2016 to 2020.

Dr. Kakinen’s research focuses on neurodegenerative diseases, particularly amyloid-related disorders such as Parkinson’s and Alzheimer’s disease. His expertise spans structural biology, protein aggregation, neuroinflammation, and nanomedicine, with a special emphasis on developing brain-targeted delivery systems for neuroprotective therapies.

He has authored over 65 peer-reviewed publications in leading journals including Nature Communications, Advanced Science, ACS Nano, and Chemical Society Reviews. Dr. Kakinen also leads a research team that combines fundamental biophysics with translational studies to advance treatments for neurodegenerative disorders.

In addition to his scientific work, he founded a design studio specialising in scientific illustrations and biomedical animations, enhancing science communication through creative visual storytelling.

Cognitive and decision-making problems associated with psychotic disorders like schizophrenia are considered the largest burden for these individuals. They also predict poor functional outcomes, such as maintaining work, social networks, and independent living. I am particularly interested in the relationship between decision-making problems and psychotic symptoms in these disorders; will improving decision-making also reduce psychotic symptoms? To that end, I focus on decision-making tasks that are reliant on brain areas and networks that are implicated in psychosis.

My work aims to understand how corticostriatal circuitry drives decision-making processes, and how this is altered in those with schizophrenia and psychosis. I have taken advantage of my collaborations with basic scientists and clinical researchers with a broad range of expertise to establish a cross-species program of research focussed on decision-making. My research is guided by two fundamental questions:

1. Do decision-making problems in schizophrenia and other psychotic disorders contribute to psychotic symptoms?
2. How can we leverage the mechanistic tools available in rodent neuroscience to identify causative common substrates underlying decision-making problems (and by proxy psychotic symptoms)?

How to build a brain—2.0

For 25 years I was sole chief investigator on 17 NHMRC-ARC project grants that provided funding to decipher the molecular & cellular bases of brain development and regeneration in fish, frogs and mice. This work culminated in the discovery of how to genetically construct an evolutionary novel axon tract in the embryonic brain. This is what I now call an easy problem.

Now my lab has turned its attention to the hardest problem in the natural sciences—how does the brain experience subjective feelings?

Together with my collaborator Professor Deborah Brown (Professor of Philosophy at UQ) we have approached this problem through the sensation of pain and model organisms. We advance the framework of the brain as an inference machine that generates models of its own internal processes (Key and Brown, 2018). When hierarchically arranged, the outputs of these models represent progressive levels of awareness that are antecedent to feelings (i.e. the brain’s experience of its own neural activity). We have proposed a parallel forwards model algorithm and to date have found that fish and molluscs lack the required neural architecture to execute this algorithm and therefore do not feel pain.

Key, B. and Brown, D. (2018) Designing brains for pain: Human to mollusc. Frontiers in physiology 9:1027.

I am a developmental neuroscientist and bioinformatician interested in the molecular evolution of the mammalian brain. I completed a PhD on the molecular development of vasculature in the primate retina at the Australian National University, followed by a postdoctoral position at the Institut de la Vision in France that was supported by a NHMRC CJ Martin fellowship, where I investigated the role of guidance factors in the formation of commissural neurons within the mammalian hindbrain. My current research focuses on the development and evolution of the mammalian forebrain, in particular understanding the regulatory mechanisms and molecular evolutionary processes that control specification of cortical neuron subtypes.

Dr Nyoman Kurniawan is a Senior Research Fellow in the Centre for Advanced Imaging and the Facility Manager for Preclincal 16.4T Microimaging 9.4T MRI scanners.

Dr Kurniawan’s research areas are:

• Diffusion magnetic resonance imaging of mouse neuroanatomy, with view to study neurological disease model, including:
  • developmental abnormalities
  • spinal cord diseases
• Development of 3D mouse brain, human spinal cord and cephalopod brain atlases using high resolution structural and diffusion MRI
• Development of MR methods for nephron imaging
• Application of MRI for agriculture imaging

Dr Mia Langguth is a Research Fellow at the Queensland Brain Institute at the University of Queensland, in Brisbane, Australia. Together with Professor Darryl Eyles and Dr Xiaoying Cui at the Queensland Centre for Mental Health Research, her research explores the metabolic side effects of anti-psychotic drugs (APDs) and if intranasal, rather than oral, administration of clozapine and other APDs might mitigate the severity of the debilitating side effects of drugs used to treat symptoms of schizophrenia.

Dr John Lee is the Ross Maclean Senior Research Fellow and a Group Leader at the Queensland Brain Institute (QBI). He holds a joint appointment at UQ’s School of Biomedical Sciences. A mid-career researcher with training in neuroscience, pharmacology, and inflammatory pathways, including the complement system and inflammasomes in motor neuron disease (MND), Huntington’s disease, and Parkinson’s disease.

Dr. Lee completed his PhD at UQ in 2014, before pursuing postdoctoral research in neuroinflammation and neurodegeneration. His translational studies have demonstrated the therapeutic potential of anti-inflammatory compounds to reduce neuronal cell death in animal models, with one candidate advancing to Phase 1B clinical trials. He is also collaborating on novel liquid drug formulations to meet the needs of MND patients who lose the ability to swallow.

Supported by the Ross Maclean Fellowship, which was established in memory of Ross Maclean, who lost his battle with MND in 2005, Dr Lee is working to accelerate drug programs towards the clinic and improve the quality of life for people living with MND.

Dr Odette Leiter is a postdoctoral research fellow in the research group of Dr Tara Walker, investigating systemic brain rejuvenation. She was awarded a PhD in Neuroscience in 2018 by the Technische Universität Dresden in Germany. Her research focus lies on the regulation of adult hippocampal neurogenesis by physical exercise, a process critically involved in learning and memory.

To support her research at the Queensland Brain Institute, Dr Odette Leiter has received two postdoctoral fellowships, a postdoctoral fellowship from the German Academic Exchange Service, followed by a Walter Benjamin Fellowship awarded by the German Research Foundation, allowing her to investigate the role of platelets in mediating neurogenesis-related learning and memory, and the capacity of platelet-released factors to restore cognitive function in ageing. More recently, Dr Leiter has been awarded a Discovery Early Career Researcher Award (DECRA) to investigate the precise mechanisms through which platelets interact with adult hippocampal neural stem cells following exercise.

Zhiqi Liang is a Specialist Musculoskeletal Physiotherapist and Lecturer in Physiotherapy at the University of Queensland. She teaches on the Master of Physiotherapy (Musculoskeletal) Program and maintains a clinical role at the Headache Clinic in the University of Queensland. Her research is on neck pain and headache, especially migraine, exploring mechanisms of neck pain in headache and treatment directions, including patient preferences, for individualised management. In 2024, she was awarded the David Lamb Award by the International Federation of Manual and Musculoskeletal Physical Therapists Incorporated (IFOMPT) for high quality research that has made an impact to musculoskeletal physiotherapy internationally. Zhiqi has been a musculoskeletal physiotherapist for more than 15 years and her clinical expertise is recognised by Fellowship within the Australian College of Physiotherapists, where she has been actively involved as an examiner and facilitator for the Specialisation Training Program and currently serves on the Board of Censors.

Professor Jason Mattingley was appointed as Foundation Chair in Cognitive Neuroscience at the University of Queensland in January 2007, a joint appointment between the Queensland Brain Institute and the School of Psychology.

He completed a Bachelor of Science Degree with Honours at Monash University (1988), a Master of Science Degree in Clinical Neuropsychology at the University of Melbourne (1990), and a PhD in Psychology at Monash University (1995). In 1994 he was awarded an NHMRC Neil Hamilton Fairley Post-Doctoral Fellowship, which he took to the University of Cambridge. Here he worked jointly with Professor Jon Driver in the Department of Experimental Psychology and Professor Ian Robertson at the MRC Cognition and Brain Sciences Unit. While in Cambridge he was elected a Fellow of King’s College.

Upon returning to Australia Professor Mattingley was appointed as Senior Research Fellow (later Principal Research Fellow) at the University of Melbourne, where he was Director of the Cognitive Neuroscience Laboratory within the School of Behavioural Science (2000 – 2006).

Professor Mattingley has won numerous accolades for his research, including an Australian Laureate Fellowship from the Australian Research Council (2012), the Distinguished Contribution to Psychological Science Award from the Australian Psychological Society (2012), and the Monash University Distinguished Alumni Award (Faculty of Biomedical and Psychological Sciences, 2016).

He was elected a Fellow of the Academy of Social Sciences in Australia in 2007, and a Fellow of the Association for Psychological Science in 2016.

John McGrath AM, MBBS, MD, PhD, FRANZCP, FAHMS

John McGrath is a psychiatrist interested in discovering the causes of serious mental disorders. He is the Director of the Queensland Centre for Mental Health Research and conjoint Professor at the Queensland Brain Institute His research aims to generate and evaluate nongenetic risk factors for schizophrenia. He has forged productive cross-disciplinary collaborations linking risk factor epidemiology with developmental neurobiology. For example, John and his colleagues have made discoveries linking prenatal vitamin D and later risk of mental illness in the offspring. In addition, John has supervised major systematic reviews of the epidemiology of schizophrenia. He was awarded a John Cade Fellowship by the Australian National Health and Medical Research Council. In 2016 he was also awarded a Neils Bohr Professorship by the Danish National Research Foundation.

Associate Professor Treasure McGuire graduated with a Bachelor of Pharmacy and a Bachelor of Science (Pharmacology) from the University of Queensland UQ). She also completed a Postgraduate Diploma in Clinical Pharmacy and Graduate Certificate in Higher Education at UQ. In 2005, she completed her PhD in the School of Population Health, UQ, entitled Consumer medicines call centres: a medication liaison model of pharmaceutical care.

She held a conjoint appointment between the School of Pharmacy, UQ and Mater Pharmacy, Mater Health, South East Queensland between 1996 and December 2022. She was appointed as a Senior Lecturer in 2006, Associate Professor, Clinical in 2021 and since 2023 Honorary Associate Professor. Treasure also holds a conjoint appointment between Mater and the Faculty of Health Sciences and Medicine, Bond University as Associate Professor of Pharmacology. In her clinical role at Mater, she is Assistant Director of Pharmacy (Practice and Development). At UQ, she coordinated a graduate clinical pharmacy course within the Master of Clinical Pharmacy program for over a decade. In 2016, this program received a UQ Faculty of Health and Behavioural Sciences Team Award for Programs that Enhance Learning and in 2017 a citation in the University of Queensland Award for Excellence in Teaching and Learning.

Treasure’s research is translational, focusing on patient centred-care and quality use of medicines in the domains of medicines information, evidence-based practice, medication safety, reproductive health, complementary medicines, communicable diseases and interprofessional education. She is a Emeritus Fellow of the Australasian College of Pharmacy, Fellow of the Pharmaceutical Society of Australia and Foundation Fellow, Australian and New Zealand College of Advanced Pharmacy. In recognition of her services to medicines information, she received the Lilly International Fellowship in Hospital Pharmacy and the Bowl of Hygeia of the Pharmaceutical Society of Australia. In 2015, she was the recipient of the Sr Eileen Pollard Medal (Mater Research-UQ) for excellence in incorporating research into clinical care provision.